Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

LIV-3D-QSAR models for PGI2 receptor ligands using multiple conformations.

Rita Cristina Azevedo Martins1, Magaly Girão Albuquerque, Ricardo Bicca de Alencastro

  • 1Laboratório de Modelagem Molecular (LabMMol), Departamento de Química Orgânica, Instituto de Química, Universidade Federal do Rio de Janeiro, Cidade Universitária, CT, Bloco A, Sala 609, Rio de Janeiro, RJ 21949-900, Brasil.

European Journal of Medicinal Chemistry
|April 10, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrative in silico and in vitro discovery of a novel thiazolidinone derivative as arginase inhibitor with potent antileishmanial activity.

Chemico-biological interactions·2026
Same author

Cafestol-derivatives as potential FXR agonists and CYP7A1 inhibitors and their impact on hypercholesterolemia: an in silico study.

Scientific reports·2026
Same author

Machine Learning and Molecular Modeling for Drug Repurposing Targeting Potential PI3Kα Inhibitors in Post-CoViD-19 Pulmonary Fibrosis.

ACS omega·2026
Same author

Statine-based peptidomimetics as SARS-CoV-2 Papain-like protease inhibitors: in Silico and in vitro studies.

Scientific reports·2025
Same author

In silico evaluation of N-aryl-1,10-phenanthroline-2-amines as potential inhibitors of T. cruzi GP63 zinc-metalloprotease by docking and molecular dynamics simulations.

Scientific reports·2025
Same author

In vitro assays identified thiohydantoins with anti-trypanosomatid activity and molecular modelling studies indicated possible selective CYP51 inhibition.

Scientific reports·2025

A novel 3D descriptor, local intersection volume (LIV), aids in developing 3D-QSAR models for prostaglandin I2 (PGI2) receptor ligands. This method helps design new inhibitors of platelet aggregation.

Area of Science:

  • Medicinal Chemistry
  • Computational Chemistry
  • Pharmacology

Background:

  • The prostaglandin I2 (PGI2) receptor plays a crucial role in platelet aggregation.
  • Developing effective inhibitors of platelet aggregation is vital for cardiovascular health.
  • Existing quantitative structure-activity relationship (QSAR) models may not fully capture the complex interactions with the PGI2 receptor.

Purpose of the Study:

  • To introduce and validate a new 3D descriptor, the local intersection volume (LIV).
  • To construct robust 3D-QSAR models for PGI2 receptor ligands.
  • To facilitate the design of novel PGI2 receptor agonists and platelet aggregation inhibitors.

Main Methods:

  • Development of the local intersection volume (LIV) 3D descriptor.

Related Experiment Videos

  • Application of LIV to a set of 42 aromatic heterocyclic PGI2 receptor ligands.
  • Utilizing a combined Genetic Algorithm (GA) and Partial Least Squares (PLS) approach for model construction.
  • Analysis of 30% of generated conformations for each compound.

    • Main Results:

    • Successful construction of LIV-based 3D-QSAR models for PGI2 receptor ligands.
    • Identification of Model 3 as the statistically superior and mechanistically comprehensive model.
    • Demonstration of the model's predictive capability for agonist activities and anti-platelet aggregation effects.

    Conclusions:

    • The local intersection volume (LIV) descriptor is a valuable tool for 3D-QSAR modeling.
    • The developed LIV-3D-QSAR models provide mechanistic insights into PGI2 receptor ligand interactions.
    • The models can be effectively applied to guide the design of new PGI2 receptor ligands with desired pharmacological properties.